Abstract
BackgroundHigh mobility group protein A2 (HMGA2) overexpression has been reported to be closely related to tumor progression [1-4] and indicate significantly worse overall survival in gastric cancer [5-8]. However, a final consensus regarding this issue has not yet been reached. Thus, we conducted a meta-analysis to evaluate the association between HMGA2 expression and prognosis of gastric cancer patients.MethodsThe Cochrane Library, Embase, PubMed, Web of Science and China Biology Medicine databases were searched to identify eligible literature published prior to September 2016. In the included studies, the level of HMGA2 amplification was evaluated by immunohistochemistry. We performed a meta-analysis, and pooled relative risk (RRs), hazard ratio (HRs), and 95% confidence intervals (CIs) were analyzed using Review Manager 5.3.ResultsSix studies [5-7, 9-11] involving 712 gastric cancer patients were included and stratified by HMGA2 amplification magnitude. The results of the analysis indicated that higher HMGA2 levels were associated with several clinicopathological parameters and predicted poor prognosis in terms of overall survival (OS).ConclusionsThe results of the present study indicate that higher HMGA2 levels were significantly associated with TNM stage, lymph node status, vascular invasion, and poor OS in patients with gastric cancer. In conclusion, HMGA2 may serve as a promising prognostic biomarker in gastric cancer.
Highlights
According to Globacan (2012), gastric cancer (GC) was the fifth most common carcinoma worldwide; at that time, the overall case fatality rate in GC patients was 74.5% [12]
The results of the present study indicate that higher High mobility group protein A2 (HMGA2) levels were significantly associated with TNM stage, lymph node status, vascular invasion, and poor overall survival (OS) in patients with gastric cancer
HMGA2 may serve as a promising prognostic biomarker in gastric cancer
Summary
According to Globacan (2012), gastric cancer (GC) was the fifth most common carcinoma worldwide; at that time, the overall case fatality rate in GC patients was 74.5% [12]. Prognosis is usually assessed by TNM staging (tumor, lymph nodes and metastasis). This approach may be flawed, as prognosis often differs in patients at the same tumor stage [15]. Given this fact, it is necessary to identify a specific prognostic biomarker that can accurately identify patients with poor prognosis, allowing health care professionals to preemptively alter their treatment strategy. We conducted a meta-analysis to evaluate the association between HMGA2 expression and prognosis of gastric cancer patients
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
